References

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2400712 · 2024 · External reference

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant‐ineligible or transplant‐deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

10.1038/s41591-024-03485-7 · 2025 · External reference

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant‐ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

10.1038/s41591-024-03050-2 · 2024 · External reference

Use of daratumumab in high risk multiple myeloma: a meta‐analysis

10.1002/jha2.47 · 2020 · External reference

Evaluation of daratumumab for the treatment of multiple myeloma in patients with high‐risk cytogenetic factors: a systematic review and meta‐analysis

10.1001/jamaoncol.2020.4338 · 2020 · External reference

Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma

10.1200/jco.18.00776 · 2019 · External reference

International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high‐risk multiple myeloma

10.1200/jco-24-01893 · 2025 · External reference

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE‐MM3 and ‐MM4 trials

10.1182/blood.2022016782 · 2023 · External reference

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

10.1182/blood.2020010439 · 2022 · External reference

A DNA target‐enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

10.1038/bcj.2016.72 · 2016 · External reference

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

10.1038/s41375-018-0037-9 · 2018 · External reference

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

10.1016/s1470-2045(16)30206-6 · 2016 · External reference

High‐risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next‐generation sequencing

10.1182/blood.2025029999 · 2026 · External reference

Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta‐analysis

10.1001/jamaoncol.2016.3160 · 2017 · External reference

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

10.1182/blood-2018-06-858613 · 2018 · External reference

Measurable residual disease by next‐generation flow cytometry in multiple myeloma

10.1200/jco.19.01231 · 2020 · External reference

Definition and clinical significance of the monoclonal gammopathy of undetermined significance‐like phenotype in patients with monoclonal gammopathies

10.1200/jco.22.01916 · 2023 · External reference

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

10.1182/blood.2024026230 · 2025 · External reference

Measurable residual disease‐guided therapy in newly diagnosed myeloma

10.1056/nejmoa2505133 · 2025 · External reference

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2312054 · 2024 · External reference